Revenue
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
REGENXBIO Inc. (RGNX)
Price$8.94Cached quote
Net income
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $170.4M | $83.3M | $90.2M | $112.7M | $470.3M | $154.6M | $35.2M | $218.5M | $10.4M | $4.6M | $7.6M | $6.1M | $6.1M |
| Gross profit | $150.1M | $49.8M | $53.0M | $58.2M | $418.5M | $118.9M | $27.0M | $208.9M | $8.7M | $4.5M | $7.5M | $6.0M | $5.9M |
| Gross margin | 88.09% | 59.72% | 58.76% | 51.61% | 88.98% | 76.89% | 76.61% | 95.59% | 83.56% | 97.86% | 98.71% | 98.01% | 97.16% |
| Research & development | $228.3M | $208.5M | $232.3M | $242.5M | $181.4M | $166.3M | $124.2M | $83.9M | $57.2M | $45.5M | $17.3M | $5.0M | $5.1M |
| Operating expenses | $331.6M | $316.7M | $358.4M | $375.6M | $310.4M | $273.8M | $184.2M | $130.4M | $86.3M | $69.9M | $30.7M | $9.8M | $10.9M |
| Operating income | −$161.2M | −$233.3M | −$268.1M | −$262.9M | $160.0M | −$119.2M | −$149.0M | $88.1M | −$75.9M | −$65.3M | −$23.1M | −$3.7M | −$4.8M |
| Operating margin | −94.58% | −280.03% | −297.12% | −233.20% | 34.01% | −77.14% | −422.89% | 40.32% | −730.15% | −1,423.84% | −304.92% | −60.16% | −78.46% |
| EBITDA | −$145.6M | −$217.1M | −$250.8M | −$250.0M | $169.5M | −$110.8M | −$141.8M | $92.1M | −$73.2M | −$64.8M | −$23.1M | −$3.7M | −$4.8M |
| EBITDA margin | −85.42% | −260.57% | −277.93% | −221.75% | 36.05% | −71.70% | −402.59% | 42.14% | −704.31% | −1,411.99% | −303.86% | −60.16% | −78.46% |
| Net income | −$193.9M | −$227.1M | −$263.5M | −$280.3M | $127.8M | −$111.3M | −$94.7M | $99.9M | −$73.2M | −$63.0M | −$22.8M | −$4.0M | −$5.4M |
| Net profit margin | −113.75% | −272.54% | −291.99% | −248.68% | 27.18% | −71.98% | −268.88% | 45.74% | −704.02% | −1,372.13% | −300.62% | −65.41% | −88.50% |
| Basic EPSper basic share | -$3.76 | -$4.59 | -$6.02 | -$6.50 | $3.01 | -$2.98 | -$2.58 | $2.99 | -$2.45 | -$2.38 | -$2.59 | -$1.82 | -$2.50 |
| Diluted EPSper diluted share | -$3.76 | -$4.59 | -$6.02 | -$6.50 | $2.91 | -$2.98 | -$2.58 | $2.73 | -$2.45 | -$2.38 | -$2.59 | -$1.82 | -$2.50 |
Owners
Reported shareholders
11.81%of listed shares
BlackRock, Inc.6.4M shares · Jun 30, 2026
View holders
| Holder | % owned |
|---|---|
BlackRock, Inc. | 11.81%6.4M shares |
Redmile Group, LLC | 8.07%4.37M shares |
STATE STREET CORP | 5.49%2.97M shares |
Fox Allan M. | ≈5.38%2.91M shares |
JPMORGAN CHASE & CO | 4.09%2.21M shares |
VANGUARD CAPITAL MANAGEMENT LLC | 3.89%2.11M shares |
MORGAN STANLEY | 3.61%1.95M shares |
GOLDMAN SACHS GROUP INC | 2.62%1.42M shares |
AQR CAPITAL MANAGEMENT LLC | 2.54%1.38M shares |
VANGUARD PORTFOLIO MANAGEMENT LLC | 2.50%1.36M shares |
MARSHALL WACE, LLP | 2.37%1.28M shares |
GEODE CAPITAL MANAGEMENT, LLC | 2.29%1.24M shares |
Integral Health Asset Management, LLC | 1.48%800K shares |
Nuveen, LLC | 1.37%740.03K shares |
DIMENSIONAL FUND ADVISORS LP | 1.35%731.59K shares |
D. E. Shaw & Co., Inc. | 1.32%712.81K shares |
TWO SIGMA INVESTMENTS, LP | 1.24%669.81K shares |
CITADEL ADVISORS LLC | 1.24%669.02K shares |
STIFEL FINANCIAL CORP | 1.04%560.73K shares |
BANK OF AMERICA CORP /DE/ | 0.96%518.55K shares |
Percentages use 54.16M shares of this listed class outstanding on Jun 30, 2026. ≈ compares the latest reported holding with a share total from a different date; it is not a confirmed current stake.
Gray completes the 100% scale. Reported positions may overlap; holders have different reporting dates.
Source: SEC Form 13F ↗Updated Sep 29, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| May 11, 2026Form 4 · 10b5-1 | PAKOLA STEVEChief Medical Officer | SellCommon Stock | 15.3K | $11.02 | $168.7K | 232.6K |
| Mar 10, 2026Form 4 · 10b5-1 | PAKOLA STEVEChief Medical Officer | SellCommon Stock | 5.1K | $10.35 | $53.0K | 247.9K |
| Oct 9, 2025Form 4 · 10b5-1 | Simpson CurranChief Executive Officer | SellCommon Stock | 20.8K | $12.62 | $262.6K | 216.2K |
| Sep 29, 2025Form 4 · 10b5-1 | Simpson CurranChief Executive Officer | SellCommon Stock | 7.6K | $10.03 | $76.5K | 237.0K |
| Sep 10, 2025Form 4 · 10b5-1 | Simpson CurranChief Executive Officer | SellCommon Stock | 7.7K | $10.02 | $77.5K | 244.6K |
Community posts
REGENXBIO reports three-year durability in diabetic-retinopathy study
REGENXBIO ($RGNX) presented three-year results from ALTITUDE, its Phase 2 study of sura-vec for diabetic retinopathy. Six of ten patients in the Dose 3 group who had reached the three-year visit showed an improvement of more than two steps ...
